Stock Taper
SCREENER COMPARE ANY 2 STOCKS
CTNM
CONTINEUM THERAPEUTICS, INC.
NASDAQ
$17.05
▼ DOWN 1.16% (-0.20)

KEY STATISTICS

Market Cap$641.44 M
52w High$17.51
52w Low$8.60
Dividend Yield—
Frequency—
P/E-9.86
Volume477.84K
Shares Out.37.62M

COMPANY

LEADERSHIP

Carmine N. Stengone
CHIEF EXECUTIVE
Carmine N. Stengone

COMPENSATION 2026

Salary$655,620
Stock Awards$0
Incentive Plan Pay$450,739
All Other Comp.$11,449
Total$3,409,448

ABOUT

SECTOR
Healthcare
WENT PUBLIC
April 4, 2024
METHOD OF GOING PUBLIC
N/A
FULL TIME EMPLOYEES
51

PRICE TARGET

Target High$16.00
Target Low$16.00
Target Median$16.00
Target Consensus$16.00

UPCOMING EARNINGS

DateOct 29, 2026
DayThursday
Rev. Est.$5.65M
OCT
29
THU

PRICE

$17.05 ▼ DOWN 1.16% (−$0.20)
$16.95$17.10$17.25$17.409:30 AM10:35 AM11:40 AM12:45 PM1:49 PM2:54 PM3:59 PM17.05

About Contineum Therapeutics, Inc.

https://www.contineum-tx.com ↗

Contineum Therapeutics, Inc. is a San Diego-based clinical-stage biopharma developing novel oral small molecules for neuroscience, inflammation, and immunology, with lead assets targeting LPA1R and M1 receptors for conditions like pulmonary fibros...

INDUSTRY

Biotechnology

A PRODUCT CONTINEUM THERAPEUTICS, INC. IS KNOWN FOR

PIPE-791
PIPE-791

Contineum Therapeutics' lead drug, PIPE-791, is a small molecule LPA1 inhibitor in Phase 2 trials for IPF, PrMS, and chronic pain, with a primary focus on IPF.

COMPETITORS

COMPETITOR
AMGN COMPARE
BMY COMPARE
GPCR COMPARE
PLRX COMPARE
UTHR COMPARE

ETFS HOLDING THIS STOCK

ETFS HOLDING
66
LISTED HERE
12
RANKED BY POSITION SIZE
VTI
0.00% · 982.3K
XSU.TO
0.01% · 656.3K
SCHA
0.01% · 124.2K
DFAS
0.01% · 54.5K
AVSC
0.03% · 51.2K
ZPRR.DE
0.01% · 50.0K
SBIO
0.29% · 40.5K
GSSC
0.06% · 35.3K
XRS2.DE
0.01% · 24.6K
RSSL
0.01% · 12.7K
IBBQ
0.04% · 2.1K
BIB
0.02% · 1.2K

INSTITUTIONAL OWNERSHIP

SHARES OWNED
55.24%
HOLDERS
109
TOP 12 OF 109 · RANKED BY POSITION SIZE
Suvretta Capital Management, LLC
2.8M sh · $37.11M
Janus Henderson Group Plc
2.7M sh · $35.59M
Ra Capital Management, L.P.
2.2M sh · $24.91M
Johnson & Johnson
2.0M sh · $25.85M
Franklin Resources Inc
1.9M sh · $21.48M
Balyasny Asset Management L.P.
1.8M sh · $21.06M
Millennium Management LLC
1.5M sh · $20.05M
Perceptive Advisors LLC
1.5M sh · $16.74M
Baker Bros. Advisors LP
1.4M sh · $18.56M
Vanguard Group Inc
1.3M sh · $14.53M
Commodore Capital LP
816.3K sh · $9.33M
Fmr LLC
814.9K sh · $10.64M

RATINGS SNAPSHOT

Overall rating: C+

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book3
Overall Score2

INSIDER TRADES

★
DIRECTOR, OFFICER: CEO AND PRESIDENT
Stengone Carmine N.
Sale · 2.5K shares
2026-08-03
★
DIRECTOR, OFFICER: CEO AND PRESIDENT
Stengone Carmine N.
Purchase · 2.5K shares
2026-08-03
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Lorrain Daniel S.
Sale · 1.0K shares
2026-07-08
★
OFFICER: CHIEF SCIENTIFIC OFFICER
Lorrain Daniel S.
Sale · 25 shares
2026-07-09

MOST RECENT ANALYST GRADES

GRADE SUMMARY
OUTPERFORM 2
EQUAL WEIGHT 1
3 GRADES IN THE LAST 12 MONTHS
RBC Capital OUTPERFORM Morgan Stanley EQUAL WEIGHT Baird OUTPERFORM

SECTORS PEERS

PEERPRICE
ANRO$35.13COMPARE
CADL$13.07COMPARE
SLN$13.42COMPARE
CAPR$9.59COMPARE
KYTX$8.37COMPARE
LXEO$4.86COMPARE
AMRN$13.97COMPARE
ACIU$2.65COMPARE